Genitourinary Cancer
Conference Coverage
Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest
Cancer patients treated with immune checkpoint inhibitors are not significantly more likely to develop or die from COVID-19, two studies suggest...
Conference Coverage
Risk factors for severe immune-related AEs identified
A nationwide cohort study of more than 14,000 patients finds combination immune checkpoint inhibitor therapy, younger age, and a lung cancer...
Clinical Insights
Using telehealth to deliver palliative care to cancer patients
Dr. Alan Lyss discusses the use of telehealth for palliative cancer care, including results from the REACH PC trial.
Conference Coverage
Predictors of upstaging on PSMA PET/CT may help guide its use
Patients with high-risk prostate cancer having more positive cores on biopsy or a higher Gleason grade were most likely to experience upstaging...
From the Journals
Testicular cancer link to below-the-waist scans, x-rays?
From the Journals
New cancer drugs may have saved more than 1.2 million Americans
Cancer drugs approved between 2000 and 2016 significantly reduced deaths from the most common cancers in the United States.
From the Journals
‘Test all patients with cancer’: One in eight have inherited mutations
Nearly half of mutations identified in this study would have been missed under current guidelines.
From the Journals
One-month delay in cancer treatment linked to increase in mortality
The risk of death varied by treatment type.
From the Journals
Pembrolizumab plus axitinib continues to outshine sunitinib for advanced RCC
The combination produced a survival benefit in the overall population but not among patients with favorable-risk disease.
From the Journals
No benefit with adjuvant sorafenib in intermediate-/high-risk RCC
Survival was similar with adjuvant sorafenib and placebo.
From the Journals
Real-world results with checkpoint inhibitors found inferior to trial results
Data suggest real-world survival is worse than survival in clinical trials.